Bipolar disorders (BD) are a group of complex disorders that impact mood, behaviour and cognition and are known to cause significant suffering and impairment. Circadian rhythm (your internal day/night "clock") disruption, which can involve changes in sleep-wake cycles, frequently occurs in BD. Both depression and mania are accompanied by circadian disruption. These disruptions are hypothesized to lead to mood worsening, metabolic dysfunction and inflammation. If circadian dysfunction plays a significant role in the symptoms and trajectory of BD, then treatment approaches that target these functions may lead to better outcomes. One such approach is dietary interventions. Time restricted eating (TRE) is a dietary tool that restricts the eating to an 8-12 hour window, without changing diet quality or caloric intake. Studies involving time restricted eating have been done in other conditions with promising results. There have been no studies done for mood disorders in general or bipolar disorder specifically. In this proposal, the investigators will assess two dietary interventions (TRE and nutritional counselling) to examine how TRE may represent a safe and viable adjunct to traditional treatments. The investigators aim to compare TRE with nutritional counselling, while all participants continue to receive usual care. Participants will receive support from a registered dietician and will be instructed on dietary habits. Half of participants will receive nutritional counselling and half will be asked to do TRE. Those in the TRE group will be asked to select a 10-hour window to consume all food and non-water beverages for the 8-week period. Participants will be asked to complete a screening visit to determine eligibility, and then will complete questionnaires at baseline, week 4 and week 8 examining symptoms of their illness and cognition. Participants will also provide a blood sample at baseline and week 8 for standard biochemistry tests, pregnancy testing (if applicable), and to examine inflammatory markers. Participants will also wear an actigraphy watch which provides wireless continuous monitoring of movements and ambient light. The primary outcome is feasibility and acceptability (do people agree to participate, complete the study, and follow the intervention; what do they think of the intervention). Secondary outcomes include changes in depression, anxiety, sleep, and cognition. Exploratory outcomes include inflammatory markers and circadian disruption.

Start Date15 Jan 2025

Sponsor / Collaborator

University of Ottawa

[+1]

NCT06718439

/ Not yet recruitingNot ApplicableIIT

Threshold for Operative and Postoperative Hemoglobin Trigger for Red Blood Cell Transfusion: A Pilot Randomized Controlled Trial (TOPGUN-Pilot)

The goal of this pilot clinical trial is to learn if it is achievable to conduct a large-scale clinical trial whereby, the investigators will compare two ways of deciding when to give a blood transfusion during surgery. Participants in this study are adults undergoing surgery with a risk of significant blood loss.
The main question it aims to answer is:
* Is a trial designed to definitively test and compare two different red blood cell transfusion strategies feasible?
Participants will:
* Receive blood transfusions during surgery based on a higher (less than 90 g/L) or a lower (less than 70 g/L) hemoglobin value.
* Complete questionnaires at 30 and 90 days after surgery.

Start Date15 Jan 2025

Sponsor / Collaborator

Ottawa Hospital Research Institute

NCT06662253

/ Not yet recruitingPhase 2/3IIT

Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial

This multicentre pilot trial will assess the feasibility of a full-scale, randomized trial to determine whether bloodwork guided dosing of blood thinners reduces the risk of clotting in high-risk trauma patients. Patients will receive either standard of care dosing or dosing with adjustments based on bloodwork to achieve a minimum therapeutic threshold.

Start Date01 Jan 2025

Sponsor / Collaborator

Ottawa Hospital Research Institute

100 Clinical Results associated with Ottawa Hospital Research Institute

0 Patents (Medical) associated with Ottawa Hospital Research Institute

10,084

Literatures (Medical) associated with Ottawa Hospital Research Institute

01 Mar 2025·Journal of Clinical Epidemiology

Screening for diseases versus screening for health status

Letter

Author: Wen, Shi Wu ; Zeng, Na ; Salman, Maria ; Walker, Mark C

Disease screening aims to identify individuals at risk for specific conditions. It is expected that an early detection allows for early intervention, with improved outcomes. However, large scale screening programs may not only have implications on resources, patient outcomes may not improve but may worsen if screening for the targeted disease has not been carefully designed and executed. On the other hand, a gradience in association between the measured value in health assessment and future risks of diseases may exist for many measures such as body weight, blood pressure, and biochemical test results. The underlying risk of diseases these measures represent, such as metabolic disorders, diabetes, cardiovascular diseases, and chronic kidney diseases, tend to have a prolonged latent period. During early stage of development of these conditions, no medical intervention is needed, and lifestyle change is the most appropriate recommendation. An elevated value on these measures, although no need for medical attention, may serve as an alert for these individuals, and reinforce the urgency of lifestyle change for them. Such an alert could be great help in making changes in lifestyle, as behavioural change is one of the most challenging tasks in humanity. This could be called as screening for health status. Under this circumstance, a more liberal threshold which may include individuals not really at risk for the candidate disease, maybe acceptable, as they have no implication in resources for health care system and does not impose additional risk to individuals under screening.

01 Mar 2025·Brain Research

Aging and voluntary exercise’s effects on Aβ1-42 levels, endoplasmic reticulum stress factors, and apoptosis in the hippocampus of old male rats

Article

Author: Niazi, Mona ; Chodari, Leila ; Roshan-Milani, Shiva ; Pourheydar, Bagher ; Derafshpour, Leila ; Asghariehahari, Morteza

Within the aging cortex, amyloid beta peptide (Aβ) is a crucial element of the senile plaques, a hallmark feature often observed in cases of Alzheimer's disease (AD). The UPR (unfolded protein response), a cellular mechanism for protein folding, is switched on by Aβ accumulation. Endoplasmic reticulum (ER) stress has been identified as playing a role in aging and the development of neurodegenerative diseases. The exact molecular pathways leading to perishing of cells from Aβ-induced ER stress, as well as the impact of voluntary exercise on these mechanisms, are still subjects awaiting a definitive answer yet. In the current study, 18 male Wistar rats were included: 6 young rats (3 months old; 200-250 g) in the Young Control group, and 12 old rats (18 months old; 400-430 g) randomly allocated to the Old Control and Old Exercise groups. The rat cages had running wheels for them to voluntarily run on for 8 weeks. This was followed by Western blotting, immunohistochemical staining, biochemical as well as morphological analyses. Voluntary exercise reduced Aβ1-42 deposition (P < 0.001) and inhibited the activation of caspase-8 (P < 0.001) and caspase-12 (P < 0.01), and on top of that down-regulated the expression of ATF6 (P < 0.001), CHOP (P < 0.01), and p-PERK (P < 0.05) proteins in the hippocampus of old male rats. Exercise amplified the population of Bcl-2-expressing cells and decreased the population of Bax-expressing cells in the hippocampus of the Old Exercise group (P < 0.001). Voluntary exercise inhibited the apoptotic pathways and suppressed the activation of UPR signaling pathways. Hence, voluntary exercise may be a therapeutic strategy and a promising approach to prevent AD through modulation of Aβ-induced ER stress.

01 Mar 2025·Journal of Affective Disorders

Associations between NIH Toolbox Emotion Battery measures and previous suicide attempt in bipolar I disorder

Article

Author: Gritters, Noah M ; Harmata, Gail I S ; Fiedorowicz, Jess G ; Wemmie, John A ; Buyukgok, Deniz ; Williams, Aislinn J ; Magnotta, Vincent A ; Richards, Jenny Gringer ; Barsotti, Ercole John ; Hazegh, Pooya ; Hoth, Karin F ; Long, Jeffrey D ; Schmitz, Samantha L ; Sathyaputri, Leela

Suicide attempts are more prevalent in people with bipolar I disorder (BD-I) than in the general population. Most prior studies of suicide in BD-I have focused on separate emotion-related assays or clinician-administered scales, whereas a single, brief, and multidimensional battery of self-report measures has not yet been explored. Here, we utilized the NIH Toolbox Emotion Battery (NIHTB-EB) to assess various emotional measures, determine which were cross-sectionally associated with prior suicide attempt in BD-I, evaluate whether the NIHTB-EB could be used to identify past suicide attempt in BD-I with machine learning, and compare model performance versus using clinical mood scales. The study included 39 participants with BD-I and history of suicide attempt, 48 with BD-I without history of suicide attempt, and 58 controls. We found that 9 of the 17 measures were associated with past suicide attempt in BD-I. The initial random forest model indicated that the most important distinguishing variables were perceived stress, emotional support, anger-hostility, anger-physical aggression, perceived rejection, loneliness, and self-efficacy. Overall, the models utilizing NIHTB-EB measures performed better (69.0 % to 70.1 % accuracy) than the model containing clinical mood scale information without the NIHTB-EB measures (57.5 % accuracy). These findings suggest the NIHTB-EB could be a useful and easy-to-deploy tool in understanding the role of emotion-related measures in suicide in BD-I. Furthermore, these results highlight specific emotional subdomains that could be promising targets for longitudinal studies or interventions aimed at reducing suicide in BD-I.

News (Medical) associated with Ottawa Hospital Research Institute

09 Jan 2025

·www.prnewswire.com

Esphera SynBio Announces New Project to Advance Next Generation mRNA Vaccine Development, supported by the CQDM Quantum Leap program

OTTAWA, ON, Jan. 9, 2025 /PRNewswire/ - Esphera SynBio, a pre-clinical stage synthetic biology company, today announced a new project aimed at advancing next-generation mRNA vaccines. Using its proprietary technology, Esphera SynBio causes the production of modified nanomedicines within patients upon delivery of LNP/mRNA vaccines. These in situ produced nanomedicines can have precise targeting capabilities and tailored immunostimulatory payloads, unlocking new possibilities in vaccine innovation. This project is supported by the CQDM Quantum Leap program. "Esphera is very excited to launch this project exploring the potential enhancement of first generation LNP/mRNA vaccines by employing our transgene design to both amplify and enhance the effectiveness of these already impactful vaccines. CQDM has been instrumental in connecting Esphera with a global biopharmaceutical organization to enable this partnership." highlights Brian Lichty, co-founder and CEO of Esphera SynBio. This project leverages Esphera's innovative platform to study therapeutic nanomedicines that can act as powerful immunostimulants, delivering customized antigenic payloads to stimulate robust immune responses. "CQDM is proud to support this innovative project, led by an early-stage Canadian company, which holds the potential to develop novel therapies while fostering growth within the Canadian biopharmaceutical sector. We are also pleased to have facilitated this collaboration for Esphera by forging valuable connections with the global biopharmaceutical organization supporting this project", said Jesse Paterson, CQDM Senior Director, Business Development. About CQDM Facilitator of biopharma innovation CQDM is a not-for-profit biopharmaceutical research consortium whose mission is to support and facilitate multi-stakeholder collaborative R&D aimed at accelerating the translation of innovative technologies by the biopharma industry into solutions that address unmet medical needs, while generating significant benefits for the Quebec and Canadian economy. For more information, please visit the website: and join us on Twitter/X @CQDM_Canada and LinkedIn. About Esphera SynBio Inc. Esphera is a seed stage Canadian biotechnology combining innovative technologies developed at McMaster University and the Ottawa Hospital Research Institute. These technologies utilize synthetic biology approaches to modify cells through the expression of proprietary transgenes causing the production of engineered exosomes that serve as nanomedicines for the treatment and prevention of human disease. Esphera is developing cancer immunotherapies, vaccines and immunomodulatory therapies for a range of human diseases. To learn more please visit SOURCE Esphera SynBio Inc WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineImmunotherapymRNA

07 Jan 2025

·www.prnewswire.com

Esphera SynBio closes seed financing round to develop nanomedicine vaccines for cancer and infectious disease

Breakthrough platform of proprietary transgenes generates therapeutic exosomes in vivo OTTAWA, ON, Jan. 7, 2025 /PRNewswire/ - Esphera SynBio ("Esphera"), a synthetic biology company, today announced the closing of a $2M USD seed financing round. The financing builds on the Company's advanced R&D activities and proceeds are directed at the identification of an initial cancer vaccine clinical candidate and general corporate purposes. Seed investors GKCC and FACIT supported the financing. Using synthetic biology, Esphera produces engineered exosomes through the expression of proprietary transgenes that serve as nanomedicines. Unlocking new possibilities in vaccine innovation, the company applies the technology platform for the development of therapeutics for cancer and infectious disease. "This financing enables us to validate our vaccine platform and advance a potential best-in-class therapy for patients living with cancer," said Dr. Brian Lichty, co-founder and CEO of Esphera. "While our clear focus is on advancing toward future clinical trials, maximizing the broad potential of our technology will also necessitate the exploration of strategic partnerships." Esphera's innovative platform produces therapeutic nanomedicines that can act as powerful immunostimulants, delivering customized antigenic payloads to stimulate robust immune responses. These nanomedicines are designed to enhance the efficacy of vaccines, offering personalized solutions to combat infectious disease. "With the fields of engineered exosomes and therapeutic vaccines undergoing rapid evolution, Esphera's pioneering approach places the Company at the forefront of a transformative opportunity for patient care," said Dr. David O'Neill, Chair of the Board of Directors of Esphera and President of FACIT. "Esphera's team of entrepreneurial scientific leaders has the experience required to build a strong pipeline of innovative therapeutics." The Company is based on foundational intellectual property from the labs of Drs. Carolina Ilkow and John Bell at The Ottawa Hospital Research Institute and Dr. Lichty at McMaster University, and operates research facilities in Hamilton, Ontario and Ottawa, Ontario. About Esphera SynBio Inc. Esphera is a seed stage Canadian biotechnology company combining innovative technologies developed at McMaster University and the Ottawa Hospital Research Institute. These technologies utilize synthetic biology approaches to modify cells through the expression of proprietary transgenes causing the production of engineered exosomes that serve as nanomedicines for the treatment and prevention of human disease. Esphera is developing cancer immunotherapies, vaccines and immunomodulatory therapies for a range of human diseases. To learn more please visit espherasynbio.ca. SOURCE Esphera SynBio WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

VaccineImmunotherapy

10 Dec 2024

·www.globenewswire.com

Brain Cancer Canada Awards a $50,000 Grant to Discover How to Use the Body’s Own Immune Cells to Attack Pediatric Brain Cancers

TORONTO, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Brain Cancer Canada is excited to announce a $50,000 grant awarded to Dr. Shawn Beug, Scientist at the Children’s Hospital of Eastern Ontario Research Institute, and his team. The project aims to create personalized therapies for pediatric brain cancers by utilizing the body’s own immune cells to combat this disease. The project proposes the use of tumor-infiltrating lymphocytes (TILs) which involves the isolation of immune cells from the patient’s tumor, expanding these immune cells outside of the body, and re-introducing these expanded immune cells back into the patient. “Pediatric malignant brain tumours are the number one cause of cancer death in children. This group of patients is in dire need of safe and effective therapies that also allow survivors a good quality of life. Cancer immunotherapy for brain tumours, a highly innovative and forward-thinking therapeutic approach, offers a path of hope for cancers that have not historically responded well to standard chemoradiation. Our research makes use of the patient's own immune cells to fight the cancer,” highlights Dr. Beug. “In Canada, cancer immunotherapy for brain tumours is in early phases of development and requires proof-of-concept data. The support from Brain Cancer Canada fundraisers, donors, and philanthropists is critical to our effort to change outcomes for pediatric brain cancer patients and their families,” says Dr. Beug. This means that collaboration will be critical to change the landscape of treatment offered. The team will be engaging with Canadian Blood Services and the Ottawa Hospital, which has a unique facility for TIL manufacturing for early phase clinical trials, to help bring the work to fruition. This project is a partnership between the Children’s Hospital of Eastern Ontario (CHEO), The University of Ottawa, The Ottawa Hospital Research Institute, Canadian Blood Services, and Tammy Bell, a highly engaged family advisor. “Pediatric brain cancer research is some of the most underfunded. Too many parents have already lost their children to this disease for which we do not yet have effective treatments.  Dr. Beug and team are at the forefront of accelerating the science that could change the treatment of these lethal brain cancers,” said Anita Angelini, Brain Cancer Canada Vice-Chair. “If we want to change outcomes for patients and families, investing in early-stage, proof-of-concept research is a must. Time is of the essence and the technologies that are available to us today, and continue to evolve, are promising. We are deeply grateful to our donors that have made investment in this research possible.” This funding will support groundbreaking studies that explore new treatment avenues, harnessing the power of the immune system to provide hope for young patients and their families facing this devastating disease. For more details about this leading-edge research initiative and other efforts by Brain Cancer Canada, please contact: sac@braincancercanada.ca     Brain Cancer Canada is a national charity dedicated to supporting individuals diagnosed with malignant brain tumors. Through funding innovative research, neurosurgical technology, and advocating for increased options for treatments, Brain Cancer Canada aims to improve survival rates and the quality of life for patients, while providing essential support to their families.     This funding reflects our unwavering commitment to support research in pediatric brain cancer, addressing an inequity in funding and pursuing unmet needs. Media Contact:   Media@braincancercanada.ca   If you wish to make a donation to Brain Cancer Canada, please visit: https://braincancercanada.ca/donate/ Contact Brain Cancer Canada by phone: 1-855-375-1381  #BrainCancerCanada #TheChildrensHospitalOfEasternOntatio #CHEO #DrBeug #DrLaCasse #TheUniversityOfOttawa #OttawaHospitalResearchInstitute #PediatricCancerResearch #PatientAdvocate

Immunotherapy

100 Deals associated with Ottawa Hospital Research Institute

100 Translational Medicine associated with Ottawa Hospital Research Institute

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 27 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

Phase 2 Clinical

Current Projects

Drug(Targets)	Indications	Global Highest Phase

CLIC-1901 ( CD19 )	CD19 positive Acute Lymphoblastic Leukemia More	Phase 2 Clinical
Allogeneic bone marrow-derived mesenchymal stem cell therapy(Ottawa Hospital Research Institute)	Shock, Septic More	Phase 2
Allogeneic umbilical cord-derived human mesenchymal stromal cells(Ottawa Hospital Research Institute)	Shock, Septic More	Phase 2
GSKJ-4 ( KDM6A x KDM6B )	Leukemia More	Preclinical

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis